Skip to main content

      Our opioid response: Governance

      2024 Board of Directors

      Our Board is committed to ensuring that CVS Health is developing solutions to prescription opioid abuse through expanded education, safe prescription drug disposal, utilization management, funding for treatment and recovery programs and advocating for legislative and regulatory changes. Within the Board, the Audit Committee, the Medical Affairs Committee, the Nominating and Corporate Governance Committee and the Management Planning and Development Committee each play a significant role in the Board’s oversight efforts.

      Audit Committee

      Our Audit Committee oversees our compliance program, which includes matters related to our anti-diversion program and other controls related to opioid misuse and abuse. The Audit Committee also reviews matters related to compliance with federal health care program requirements and oversaw compliance with our Corporate Integrity Agreements, or CIAs. 

      The General Counsel also provides regular reports to the Audit Committee about litigation and investigations, which include significant government investigations, regulatory and legal matters related to prescription opioid misuse and abuse. The Chief Compliance Officer provides regular reports to the Audit Committee regarding compliance matters related to opioids. The General Counsel has regularly updated the Audit Committee and the Board on the Multi-District Litigation in the U.S. District Court of the Northern District of Ohio, its global settlement entered into in 2023, and other opioid-related matters. The General Counsel and other members of senior management participate in these reports to the Audit Committee and the Board, as appropriate.

      Medical Affairs Committee

      The Medical Affairs Committee oversees the Company’s medical- and pharmacy-related strategies and initiatives, including programs related to combatting prescription opioid and other controlled substance misuse and abuse.

      Nominating and Corporate Governance Committee

      The Nominating and Corporate Governance Committee is responsible for oversight of our corporate governance matters, including review and consideration of our public policy and government affairs practices, policies and practices on issues relating to corporate social responsibility and other significant public policy issues.

      Management Planning and Development Committee

      The Management Planning and Development Committee oversees our compensation and benefits policies and programs, including the performance of designated senior executives and our Chief Executive Officer. As part of its review, the Management Planning and Development Committee performs a comprehensive assessment of all major components of our compensation programs, including our recoupment policies. Since 2009, we have maintained a recoupment policy that applies to all annual and long-term incentive awards granted to executive officers. The policy applies in cases where financial or operational results used to determine an award amount are meaningfully altered based on fraud or material financial misconduct. In March 2019, we amended our recoupment policy to further increase transparency. The amendment requires us to publicly disclose the circumstances of any recoupment from any executive officer to the extent the underlying event has already been publicly disclosed, would not violate applicable law or is likely to result in litigation, investigation or proceedings against us. In 2023, we adopted an additional Dodd-Frank Clawback Policy that was required under SEC and New York Stock Exchange rules.

      Information about the Board, its Committees, including membership and charters, can be found on the Investor Relations site and in the 2023 Proxy Statement (PDF).

      Read more information on our comprehensive opioid action plan